Fed holds rates steady despite concerns over inflation

As the Federal Reserve is widely expected to maintain interest rates steady this afternoon, companies facing significant debt burdens may encounter elevated refinancing expenses during the upcoming quarter, potentially eroding net margins. Conversely, businesses that generate substantial free cash flow and self-fund their operations are less vulnerable to higher borrowing costs.

In a credit environment where rates are expensive, the durability of a company's balance sheet becomes a more critical factor than market rate forecasts.

InvestingPro has identified a concentrated portfolio of proven wealth generators, featuring global logistics monopolies, pharmaceutical leaders, and two deeply discounted blue-chip companies. These companies are generating billions in organic cash flow and exhibit strong financial health. Adobe Inc (NASDAQ:ADBE), priced near $249.07, has experienced a 28% decline over the past year, trading at a discounted valuation.

Despite this, Adobe demonstrates great financial health with 89.3% gross margins and $25.97 billion in revenue over the trailing twelve months, accompanied by $9.43 billion in operating income. Notably, Adobe operates without reliance on debt markets for its operations, holding $5.64 billion in cash and short-term investments against $6.79 billion in total debt.

The company's impressive cash flow of $10.81 billion over the past year supports a free cash flow yield of 10.9% and interest coverage exceeding 40 times. At just 10.3 times forward earnings, Adobe's valuation is significantly lower than industry norms, with InvestingPro estimating its Fair Value at $407.67 per share, representing a 63.7% upside potential.

In the healthcare sector, UnitedHealth Group (NYSE:UNH) stands out as a resilient company largely insulated from higher borrowing costs due to its essential role in providing medical care. In the third quarter, UnitedHealth reported adjusted earnings of $4.69 per share, surpassing consensus estimates by 13.8% and year-over-year growth of 60.6%.

The company has raised its full-year profit guidance to at least $20.50 per share. Over the past year, UnitedHealth generated $26.2 billion in operating cash flow and returned $11.2 billion to shareholders through buybacks and dividends, driven by a 16-year dividend growth streak. Operating with a low five-year beta of 0.61, UnitedHealth's business experiences less volatility compared to debt-sensitive growth stocks.

Despite these predictable cash flows, the company trades at a reasonable valuation of 19.8 times forward earnings near $414.13. InvestingPro estimates UnitedHealth's Fair Value at $539.86 per share, projecting a 30.4% upside with a steady 2.3% dividend yield.

When the Federal Reserve holds rates steady, market multiple expansion typically slows. In this environment, returns are driven by operating fundamentals, rewarding companies that generate reliable cash flow and fund their operations independently of borrowing costs. InvestingPro's screening models focus on balance-sheet solvency, margin durability, and return on equity to identify resilient businesses.

While UnitedHealth Group is already included in premier strategies such as Dominate the Dow and Best of Buffett, investors can explore a broader selection of top-ranked compounders, including new additions arriving in the November 1st rebalance, through InvestingPro. Access to this systematic approach costs just $9 a month. The author holds no position in the mentioned stocks, and data and financial metrics are current as of October 28, 2026.